JP6611720B2 - 熱安定性ワクチン製剤及びマイクロニードル - Google Patents

熱安定性ワクチン製剤及びマイクロニードル Download PDF

Info

Publication number
JP6611720B2
JP6611720B2 JP2016540347A JP2016540347A JP6611720B2 JP 6611720 B2 JP6611720 B2 JP 6611720B2 JP 2016540347 A JP2016540347 A JP 2016540347A JP 2016540347 A JP2016540347 A JP 2016540347A JP 6611720 B2 JP6611720 B2 JP 6611720B2
Authority
JP
Japan
Prior art keywords
vaccine composition
maltodextrin
vaccine
influenza
excipients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016540347A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016535065A (ja
JP2016535065A5 (enExample
Inventor
ジョセフ ミスティリス，マシュー
クリストファー エデンズ，ウィリアム
セバスチャン ボマリウス，アンドレアス
プラウスニツ，マーク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgia Tech Research Corp
Original Assignee
Georgia Tech Research Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgia Tech Research Corp filed Critical Georgia Tech Research Corp
Publication of JP2016535065A publication Critical patent/JP2016535065A/ja
Publication of JP2016535065A5 publication Critical patent/JP2016535065A5/ja
Priority to JP2019082137A priority Critical patent/JP7358068B2/ja
Application granted granted Critical
Publication of JP6611720B2 publication Critical patent/JP6611720B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
JP2016540347A 2013-09-03 2014-09-03 熱安定性ワクチン製剤及びマイクロニードル Active JP6611720B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019082137A JP7358068B2 (ja) 2013-09-03 2019-04-23 熱安定性ワクチン製剤及びマイクロニードル

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361873032P 2013-09-03 2013-09-03
US61/873,032 2013-09-03
US201361873419P 2013-09-04 2013-09-04
US61/873,419 2013-09-04
PCT/US2014/053902 WO2015034924A1 (en) 2013-09-03 2014-09-03 Thermally stable vaccine formulations and microneedles

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019082137A Division JP7358068B2 (ja) 2013-09-03 2019-04-23 熱安定性ワクチン製剤及びマイクロニードル

Publications (3)

Publication Number Publication Date
JP2016535065A JP2016535065A (ja) 2016-11-10
JP2016535065A5 JP2016535065A5 (enExample) 2017-10-12
JP6611720B2 true JP6611720B2 (ja) 2019-11-27

Family

ID=52628897

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016540347A Active JP6611720B2 (ja) 2013-09-03 2014-09-03 熱安定性ワクチン製剤及びマイクロニードル
JP2019082137A Active JP7358068B2 (ja) 2013-09-03 2019-04-23 熱安定性ワクチン製剤及びマイクロニードル

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019082137A Active JP7358068B2 (ja) 2013-09-03 2019-04-23 熱安定性ワクチン製剤及びマイクロニードル

Country Status (8)

Country Link
US (1) US10736840B2 (enExample)
EP (1) EP3041504B1 (enExample)
JP (2) JP6611720B2 (enExample)
CN (1) CN105579059B (enExample)
CA (1) CA2923010C (enExample)
ES (1) ES2897659T3 (enExample)
RU (1) RU2720808C2 (enExample)
WO (1) WO2015034924A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0402131D0 (en) 2004-01-30 2004-03-03 Isis Innovation Delivery method
EP2765927B1 (en) 2011-10-12 2021-02-24 Vaxxas Pty Limited Delivery device
KR20160147960A (ko) 2014-04-25 2016-12-23 아지노모토 가부시키가이샤 면역자극제
EP4218892A1 (en) 2015-02-02 2023-08-02 Vaxxas Pty Limited Microprojection array applicator
US20160296149A1 (en) * 2015-04-08 2016-10-13 Sandia Corporation In Vivo Extraction of Interstitial Fluid Using Hollow Microneedles
CN104984357B (zh) * 2015-06-02 2018-01-30 长春百克生物科技股份公司 不含明胶的疫苗保护剂组合物及流感减毒活疫苗
US11103259B2 (en) 2015-09-18 2021-08-31 Vaxxas Pty Limited Microprojection arrays with microprojections having large surface area profiles
AU2016333148B2 (en) 2015-09-28 2021-10-14 Vaxxas Pty Limited Microprojection arrays with enhanced skin penetrating properties and methods thereof
HK1254838A1 (zh) * 2015-10-06 2019-07-26 Janssen Vaccines & Prevention B.V. 用於预防生物制品的塑料诱导降解的方法
EP3368508A1 (en) 2015-10-28 2018-09-05 Ajinomoto Co., Inc. Immunostimulating agent
TW201722478A (zh) * 2015-11-27 2017-07-01 Nitto Denko Corp 流感疫苗乾燥製劑、及流感疫苗乾燥製劑之製造方法
US10744197B2 (en) * 2015-11-27 2020-08-18 Nitto Denko Corporation Vaccine pharmaceutical composition for oral administration and method for manufacturing vaccine pharmaceutical composition for oral administration
TW201720426A (zh) * 2015-11-27 2017-06-16 Nitto Denko Corp 流感疫苗乾燥製劑、及流感疫苗乾燥製劑之製造方法
AU2017207744A1 (en) 2016-01-11 2018-07-26 Verndari, Inc. Microneedle compositions and methods of using same
JP7101121B2 (ja) 2016-03-01 2022-07-14 ジョージア テック リサーチ コーポレイション マイクロニードル粒子、組成物、治療方法、及び目的の物質の送達方法
CN115923337A (zh) 2017-03-31 2023-04-07 瓦克萨斯私人有限公司 用于涂覆表面的设备和方法
WO2018227246A1 (en) 2017-06-13 2018-12-20 Vaxxas Pty Limited Quality control of substrate coatings
US11464957B2 (en) 2017-08-04 2022-10-11 Vaxxas Pty Limited Compact high mechanical energy storage and low trigger force actuator for the delivery of microprojection array patches (MAP)
AU2018315629B2 (en) * 2017-08-10 2025-06-26 Vaxxas Pty Limited Differential coating of microprojections and microneedles on arrays
CN110870913A (zh) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 氨基酸类营养素作为疫苗佐剂的应用以及包含氨基酸营养素作为佐剂的疫苗
JP7660514B2 (ja) * 2019-02-15 2025-04-11 セラム インスティチュート オブ インディア プライベイト リミテッド 弱毒生インフルエンザワクチン組成物及びその調製プロセス
TW202100197A (zh) * 2019-03-28 2021-01-01 日商富士軟片股份有限公司 含有流感疫苗的微針陣列及微針陣列之製造方法
AU2020255670B2 (en) * 2019-03-29 2025-12-11 Vaxxas Pty Ltd Vaccination using high-density microprojection array patch
US12005220B2 (en) * 2019-11-22 2024-06-11 Veradermics Incorporated Microneedle patch for immunostimulatory drug delivery
CN111154833B (zh) * 2020-01-03 2022-08-23 浙江夸克生物科技有限公司 一种α-L-岩藻糖苷酶测定试剂盒
US20230233373A1 (en) * 2020-06-11 2023-07-27 Aquavit Pharmaceuticals, Inc. Methods and compositions for delivering bioactive compositions to ocular tissue using microneedle devices
CA3212891A1 (en) * 2021-03-23 2022-09-29 Veradermics Incorporated Perilesional treatment of skin conditions
AU2022398370A1 (en) * 2021-11-25 2024-05-30 Orexo Ab Pharmaceutical composition comprising biopharmaceutical drug compounds
WO2025013783A1 (ja) * 2023-07-07 2025-01-16 ナガセヴィータ株式会社 タンパク質の変性抑制用組成物
US20250325286A1 (en) * 2024-04-17 2025-10-23 Micron Biomedical, Inc. Methods and Microneedle Devices for Vaccinations with Enhanced Delivery and Acceptance

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064580A1 (en) 1998-06-10 1999-12-16 Georgia Tech Research Corporation Microneedle devices and methods of manufacture and use thereof
US6503231B1 (en) 1998-06-10 2003-01-07 Georgia Tech Research Corporation Microneedle device for transport of molecules across tissue
US6743211B1 (en) 1999-11-23 2004-06-01 Georgia Tech Research Corporation Devices and methods for enhanced microneedle penetration of biological barriers
US6623457B1 (en) 1999-09-22 2003-09-23 Becton, Dickinson And Company Method and apparatus for the transdermal administration of a substance
WO2002064193A2 (en) 2000-12-14 2002-08-22 Georgia Tech Research Corporation Microneedle devices and production thereof
US6887484B2 (en) * 2001-07-31 2005-05-03 Posco Vaccine composition containing a promoter peptide
US6945952B2 (en) 2002-06-25 2005-09-20 Theraject, Inc. Solid solution perforator for drug delivery and other applications
US8062573B2 (en) 2002-09-16 2011-11-22 Theraject, Inc. Solid micro-perforators and methods of use
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
EP1633250A2 (en) 2003-06-04 2006-03-15 Georgia Tech Research Corporation Drilling microneedle device
US9744227B2 (en) 2004-06-02 2017-08-29 Universal Stabilization Technologies, Inc. Compositions containing ambient-temperature stable, inactivated but therapeutically active biopharmaceuticals and methods for formulation thereof
GB0416694D0 (en) * 2004-07-27 2004-09-01 Univ Strathclyde Process for preparing microcrystals
US20080269666A1 (en) 2005-05-25 2008-10-30 Georgia Tech Research Corporation Microneedles and Methods for Microinfusion
WO2006138719A2 (en) 2005-06-17 2006-12-28 Georgia Tech Research Corporation Coated microstructures and method of manufacture thereof
SI1954308T1 (sl) 2005-09-16 2011-12-30 Merial Ltd Stabilizatorji za liofilizirana cepiva
US20090182306A1 (en) 2006-07-21 2009-07-16 Georgia Tech Research Corporation Microneedle Devices and Methods of Drug Delivery or Fluid Withdrawal
UA97391C2 (ru) 2007-03-09 2012-02-10 Оцука Фармасьютикал Ко., Лтд. Лиофилизированный препарат, содержащий гриппозную вакцину, и способ его получения
WO2009048607A1 (en) 2007-10-10 2009-04-16 Corium International, Inc. Vaccine delivery via microneedle arrays
GB0725018D0 (en) 2007-12-21 2008-01-30 Univ Cardiff Monitoring system for microneedle delivery
CA2716546A1 (en) 2008-02-25 2009-09-03 Novavax, Inc. Sugar glassified virus like particles (vlps)
MX2010008799A (es) * 2008-03-05 2010-09-07 Sanofi Pasteur Proceso para estabilizar una composicion de vacuna que contiene adyuvante.
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
US9028463B2 (en) 2008-06-30 2015-05-12 Hisamitsu Pharmaceutical Co., Inc. Microneedle device, and method for enhancing the efficacy of influenza vaccine by using microneedle device
PT2410981T (pt) * 2009-03-26 2017-05-25 Pulmatrix Inc Formulações em pó seco e métodos para tratar doenças pulmonares
US8865182B2 (en) * 2009-07-31 2014-10-21 Paxvax, Inc. Adenoviral-based vectors
US20110243988A1 (en) 2009-10-01 2011-10-06 Aridis Pharmaceuticals Methods and Compositions for Stabilization of a Virus Vaccine
US8557253B2 (en) * 2009-10-07 2013-10-15 Sanofi Pasteur Sa Stabilizing excipient for inactivated whole virus vaccine
US10206960B2 (en) 2010-03-31 2019-02-19 Stabilitech Biopharma Ltd Stabilisation of viral particles
US9687536B2 (en) 2010-04-15 2017-06-27 Shin Nippon Biomedical Laboratories, Ltd. Methods and compositions for intranasal delivery
GB201007207D0 (en) 2010-04-29 2010-06-16 Univ Cork Method
AU2011262312B2 (en) 2010-06-01 2015-05-28 Novartis Ag Concentration and lyophilization of influenza vaccine antigens
WO2011156641A2 (en) 2010-06-09 2011-12-15 Kaspar Roger L Microneedle arrays for active agent delivery
JP5808102B2 (ja) 2010-07-22 2015-11-10 コスメディ製薬株式会社 抗原を含有する経皮免疫製剤およびその製造方法
US9517205B2 (en) 2010-08-20 2016-12-13 Seqirus UK Limited Soluble needle arrays for delivery of influenza vaccines
JP5558311B2 (ja) 2010-10-27 2014-07-23 株式会社バイオセレンタック ワクチン抗原表皮デリバリー用溶解性３層マイクロニードル・アレイ・パッチ
US9089677B2 (en) 2011-01-25 2015-07-28 The Regents Of The University Of California Transcutaneous multimodal delivery system (TMDS)
US20140287043A1 (en) * 2011-04-21 2014-09-25 Trustees Of Tufts College Compositions and methods for stabilization of active agents
AU2012255132B2 (en) 2011-05-17 2017-05-25 Soligenix, Inc. Thermostable vaccine compositions and methods of preparing same
US20130096532A1 (en) 2011-10-17 2013-04-18 Rutgers, The State University Of New Jersey Polymer-Based Micro-Needle Array Designs, Fabrication Processes, and Methods of Use Thereof for Drug Delivery
AU2012345768B2 (en) * 2011-11-30 2016-05-12 Kindeva Drug Delivery L.P. Microneedle device having a peptide therapeutic agent and an amino acid, methods of making and using the same
JP2015515474A (ja) 2012-04-03 2015-05-28 セラジェクト， インコーポレイテッド ワクチンの経頬送達のための溶解性微小針アレイ
US20130345638A1 (en) 2012-06-25 2013-12-26 Flugen, Inc. Multiple drug delivery device
EP2968162B1 (en) 2013-03-15 2020-12-02 Incube Labs, Llc Multi-stage biodegradable drug delivery platform
US10010499B2 (en) 2014-11-03 2018-07-03 Merial Inc. Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus

Also Published As

Publication number Publication date
EP3041504B1 (en) 2021-08-25
EP3041504A1 (en) 2016-07-13
JP2019163271A (ja) 2019-09-26
JP2016535065A (ja) 2016-11-10
CN105579059A (zh) 2016-05-11
RU2016111354A (ru) 2017-10-09
JP7358068B2 (ja) 2023-10-10
RU2016111354A3 (enExample) 2018-07-16
ES2897659T3 (es) 2022-03-02
US10736840B2 (en) 2020-08-11
EP3041504A4 (en) 2018-02-21
CA2923010A1 (en) 2015-03-12
CN105579059B (zh) 2020-07-31
US20160220483A1 (en) 2016-08-04
CA2923010C (en) 2022-08-30
WO2015034924A1 (en) 2015-03-12
RU2720808C2 (ru) 2020-05-13

Similar Documents

Publication Publication Date Title
JP7358068B2 (ja) 熱安定性ワクチン製剤及びマイクロニードル
Dumpa et al. Stability of vaccines
Kim et al. Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity
US12350375B2 (en) Method for obtaining efficient viral vector-based compositions for vaccination or gene therapy
Kim et al. Formulation of microneedles coated with influenza virus-like particle vaccine
DK2552465T3 (en) Stabilization of virus particles
Tian et al. Intradermal administration of influenza vaccine with trehalose and pullulan-based dissolving microneedle arrays
KR20130083376A (ko) 비강내 전달을 위한 방법 및 조성물
de Jonge et al. Inulin sugar glasses preserve the structural integrity and biological activity of influenza virosomes during freeze-drying and storage
US8216588B2 (en) Lyophilized preparation comprising influenza vaccine, and method for preparation thereof
CN102939104A (zh) 用冻干浓缩疫苗抗原
US20250057936A1 (en) Vaccine composition
US20220325250A1 (en) Method for obtaining efficient compositions comprising viral vectors for vaccination or gene therapy
BE1024160B9 (fr) Formulation immunogène
JP6469698B2 (ja) ビロソーム製剤の改良
Beukema Intradermal administration of influenza accine ith trehalose and pullulan-based dissol ing microneedle arra s
Soema Formulation of influenza T cell peptides: in search of a universal influenza vaccine
Edens MEASLES AND POLIO VACCINATION USING A MICRONEEDLE PATCH TO INCREASE VACCINATION COVERAGE IN THE DEVELOPING WORLD

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170901

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180529

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190423

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190910

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191003

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191029

R150 Certificate of patent or registration of utility model

Ref document number: 6611720

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250